Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
…, G Chrysos, A Angheben, I Kainis, Z Alexiou… - Nature medicine, 2021 - nature.com
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
…, G Adamis, A Fragkou, A Rapti, Z Alexiou… - The Lancet …, 2021 - thelancet.com
Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …
Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection
…, I Vaki, P Maravitsa, S Adamis, Z Alexiou… - Critical Care, 2010 - Springer
Introduction Although major changes of the immune system have been described in sepsis,
it has never been studied whether these may differ in relation to the type of underlying …
it has never been studied whether these may differ in relation to the type of underlying …
Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial
…, N Alexiou, S Symbardi, Z Alexiou… - American Journal of …, 2021 - atsjournals.org
Rationale: Although early antimicrobial discontinuation guided by procalcitonin (PCT) has
shown decreased antibiotic consumption in lower respiratory tract infections, the outcomes in …
shown decreased antibiotic consumption in lower respiratory tract infections, the outcomes in …
[PDF][PDF] Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure
…, E Balis, E Giannitsioti, P Rodari, I Kainis, Z Alexiou… - Cell Reports …, 2022 - cell.com
Most patients infected with SARS-CoV-2 (COVID-19) experience mild, non-specific symptoms,
but many develop severe symptoms associated with an excessive inflammatory response. …
but many develop severe symptoms associated with an excessive inflammatory response. …
A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019
…, D Jacoby, J Chittams, P Katsaounou, Z Alexiou… - Nature …, 2022 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cytotoxicity may involve
inhibition of peroxisome proliferator-activated receptor alpha. Fenofibrate activates peroxisome …
inhibition of peroxisome proliferator-activated receptor alpha. Fenofibrate activates peroxisome …
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial
…, G Schinas, L Skorda, Z Alexiou… - The Lancet …, 2024 - thelancet.com
Background Addition of macrolide antibiotics to β-lactam antibiotics for the treatment of patients
in hospital with community-acquired pneumonia is based on results from observational …
in hospital with community-acquired pneumonia is based on results from observational …
Prognostic role of soluble urokinase plasminogen activator receptor at the emergency department: a position paper by the Hellenic sepsis study group
…, G Dimopoulos, J Parissis, Z Alexiou… - Infectious diseases and …, 2020 - Springer
In light of the accumulating evidence on the negative predictive value of soluble urokinase
plasminogen activator receptor (suPAR), a group of experts from the fields of intensive care …
plasminogen activator receptor (suPAR), a group of experts from the fields of intensive care …
Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE …
…, G Chrysos, G Boni, I Kainis, Z Alexiou… - …, 2023 - thelancet.com
Background The SAVE-MORE trial demonstrated that anakinra treatment in COVID-19
pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels of 6 ng/mL or …
pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels of 6 ng/mL or …
Calprotectin and imbalances between acute-phase mediators are associated with critical illness in COVID-19
…, V Petrakis, S Sympardi, S Metallidis, Z Alexiou… - International Journal of …, 2022 - mdpi.com
The trajectory from moderate and severe COVID-19 into acute respiratory distress syndrome
(ARDS) necessitating mechanical ventilation (MV) is a field of active research. We …
(ARDS) necessitating mechanical ventilation (MV) is a field of active research. We …
